Navigation Links
Genzyme Boosts Quality Using Dyadem Quality Lifecycle Management
Date:6/5/2008

TORONTO, June 5 /PRNewswire/ -- Genzyme Corporation (Nasdaq: GENZ), one of the world's leading biotechnology companies, is enhancing the quality of the medical devices produced in its Bio-surgery division with software from Dyadem, the leader in Risk Lifecycle Management and Quality Lifecycle Management. Dyadem's FMEA-Med, a software solution that helps automate compliance reporting, enables Genzyme to link risk and quality, and to set a new standard in quality throughout the lifecycle of its biotherapeutic and biomaterial products. Genzyme's leading biomaterials and cell therapies reduce the time and complications associated with surgery, and in some cases, postpone the need for surgery.

FMEA-Med is a software solution that delivers industry-standard Failure Mode and Effects Analysis (FMEA) reports for medical devices and pharmaceutical manufacturers. FMEA methodology maintains quality and prevents potential flaws in hardware design, manufacturing and processes in a variety of industries, including pharmaceutical, automotive, and high-tech and electronics. Dyadem's FMEA-Med focuses on the entire quality lifecycle management process, which is essential to the research and advancement of these fields. The medical device industry must comply with FDA and ISO standards among others.

With more than 300 employees spanning three sites in the United States, Genzyme's Bio-surgery division now has a single standard for risk assessment. As these multiple sites are subject to varying government and industry regulatory standards, Genzyme's use of FMEA-Med creates a consistent quality standard across the division to fulfill the varying requirements.

Prior to selecting Dyadem, Genzyme used manual templates for FMEA assessments. Genzyme found that this approach led to inconsistencies in its reporting, and that it provided insufficient focus on the entire quality lifecycle. Dyadem's FMEA-Med provides a platform where clear relationships are shown between failure modes, along with their causes and net effects. This allows Genzyme to eliminate the time spent managing word processing documents, and free employee time to focus on the technical content of risk assessments.

"In our industry, quality and risk management parameters are integrated into all aspects of research, development, production and application, as our products must perform flawlessly. Dyadem's software allows us to work in a more uniform environment, and assess quality in a standard way. Our focus on increasing quality and minimizing potential risks has, in turn, favorable impact on time to market as well as reduce post-launch complaints," said Lisa Robertson, Director, Design and Development, Quality Assurance.

By achieving the high standards of quality, minimizing the risk of defects and reducing process administration, Dyadem is helping Genzyme maintain its status as an industry leader in medical research and device production.

"Achieving reduced risk through a comprehensive standard of quality should be at the top of the list for every company. In Genzyme's important industry of developing life-saving technologies, there is no room for error," said Kevin North, president and CEO of Dyadem. "Genzyme is setting an example by highlighting the importance of quality lifecycle management. Our software allows Genzyme to continue operating at an elite level to develop these life- altering technologies in an environment with high quality standards."

About Dyadem

Founded in 1993, Dyadem is the market leader in Quality Lifecycle Management and Risk Lifecycle Management solutions. Dyadem provides software and services that empower companies to manage quality, mitigate risks, achieve regulatory compliance, plan for business continuity and improve profitability. Dyadem works with 85% of the Fortune 500 companies and serves the high tech & electronics, medical devices, oil and gas, chemical, automotive, pharmaceutical and aerospace and defense industries. For more information, visit http://www.dyadem.com .

About Genzyme Corporation

One of the world's leading biotechnology companies, Genzyme Corporation (Nasdaq: GENZ) is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

For further information, contact:

Dyadem International Ltd Text 100 Public Relations

Angela Schwecke Matt Wyman

905.762.5243 617.399.4919

aschwecke@dyadem.com dyadem@text100.com


'/>"/>
SOURCE Dyadem
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Awareness of Genzymes Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected
2. Genzyme Reports Strong First-Quarter Growth
3. Genzyme to Build New R&D Center in Beijing
4. Genzyme Provides Update on Myozyme(R) Manufacturing
5. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
6. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
7. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
8. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
9. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
10. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
11. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Winston-Salem, NC (PRWEB) , ... March 27, 2017 , ... ... Clinical Trial Collaborations (CTC) conference presented by The Conference Forum in Boston ... the way they collaborate to drive improved clinical trial outcomes and bring them closer ...
(Date:3/24/2017)... MARIETTA, Ga. , March 24, 2017 ... and biopharmaceutical company utilizing human placental tissue allografts and ... therapies for multiple sectors of healthcare, announced today  that ... New York , NY.  Parker H. ... , Chief Financial Officer, Christopher M. Cashman , ...
(Date:3/24/2017)... , March 24, 2017   Sienna Biopharmaceuticals, Inc. ... company, today announced that Richard Peterson will ... 24.   Peterson, who brings more than two ... Smither , who is retiring at the end of ... advisory capacity. Peterson joins Sienna from Novan, Inc., where ...
(Date:3/23/2017)... 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), ... for solid tumor cancers, today announced that yesterday ... announced last Friday, March 17, 2017. ... securities totaling 28,843,692 shares, comprised of 18,843,692 common ... of Class C Warrants pre-funded at the closing ...
Breaking Biology Technology:
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the leading ... The Prince,s Trust to uncover insights to support its ... Trust. The UK,s leading youth charity will be using ... results and get a better understanding of the topics and issues ... ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):